Investor Relations

Amicus Therapeutics (NASDAQ: FOLD) is pioneering a paradigm-shifting approach to treating a range of human genetic diseases in which crucial proteins are misfolded, thus reducing or eliminating their functionality. Amicus develops pharmacological chaperones - oral therapies that bind to and stabilize the affected proteins, restoring their shape, proper trafficking, and biological activity. This novel, next-generation approach offers the potential to improve treatment options for patients with genetic diseases.

Recent Releases

Jun 22, 2009
Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease

May 7, 2009
Amicus Therapeutics Announces First Quarter 2009 Financial Results

Events

May 7, 2009
Amicus Therapeutics First Quarter 2009 Results Conference Call

Apr 2, 2009
BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference